BioWorld

Oct. 22, 2003

View Archived Issues

Vertex, GSK Receive Approval For Flexible HIV Drug Lexiva

Vertex Pharmaceuticals Inc. and partner GlaxoSmithKline plc won FDA approval of Lexiva, an HIV protease inhibitor that can be dosed once or twice daily, with or without food and water restrictions. (BioWorld Today) Read More

Cypress Bioscience Begins Milnacipran Phase III Trial

Read More

Cephalon's Provigil Receives Approval For Expanded Label

Read More

Biospect Raises $27M In Series A Round; Diagnostics First Focus

Read More

Other News To Note

Read More

Appointments And Advancements

Read More